MediciNova, Inc. (4875.T)
JPY 214.0
(0.47%)
JPY 214.0
(0.47%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 215.92 Thousand USD | 37.09% |
| 2022 | 157.5 Thousand USD | 19.35% |
| 2021 | 131.96 Thousand USD | -29.06% |
| 2020 | 186.02 Thousand USD | 0.0% |
| 2019 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 190.04 Thousand USD | -12.78% |
| 2024 Q1 | 217.88 Thousand USD | 0.91% |
| 2023 Q3 | 669.23 Thousand USD | -7.18% |
| 2023 Q2 | 720.96 Thousand USD | 14.15% |
| 2023 FY | 215.92 Thousand USD | 37.09% |
| 2023 Q1 | 631.57 Thousand USD | 0.0% |
| 2023 Q4 | 215.92 Thousand USD | -67.74% |
| 2022 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 2.46 Billion JPY | 99.991% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 3.69 Billion JPY | 99.994% |
| Linical Co., Ltd. | 3 Billion JPY | 99.993% |
| Trans Genic Inc. | 2.25 Billion JPY | 99.99% |
| MEDINET Co., Ltd. | 2.3 Million JPY | 90.64% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.47 Billion JPY | 99.991% |
| AnGes, Inc. | 362.67 Million JPY | 99.94% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | 99.798% |
| Nxera Pharma Co., Ltd. | 73.97 Billion JPY | 100.0% |
| Immuno-Biological Laboratories Co., Ltd. | 235.98 Million JPY | 99.908% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | 99.981% |
| Carna Biosciences, Inc. | 182.97 Million JPY | 99.882% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 885.12 Million JPY | 99.976% |
| RaQualia Pharma Inc. | 367.71 Million JPY | 99.941% |
| Chiome Bioscience Inc. | 291 Million JPY | 99.926% |
| Kidswell Bio Corporation | 2.57 Billion JPY | 99.992% |
| PeptiDream Inc. | 22.79 Billion JPY | 99.999% |
| Oncolys BioPharma Inc. | 315.17 Million JPY | 99.931% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 665 Million JPY | 99.968% |
| Healios K.K. | 4.53 Billion JPY | 99.995% |
| BrightPath Biotherapeutics Co., Ltd. | 112.5 Million JPY | 99.808% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 142.85 Million JPY | 99.849% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 97.54 Million JPY | 99.779% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 933.3 Million JPY | 99.977% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 968 Million JPY | 99.978% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 723.93 Million JPY | 99.97% |
| StemCell Institute Inc. | 8.78 Million JPY | 97.542% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 151.25 Million JPY | 99.857% |